KAINOS Laboratories, Inc. is pricipally engaged in researching, developing, manufacturing and selling clinical diagnostic reagents, including biochemical diagnostic reagents such as renal function related reagents and automatic biochemical analytical reagents, immune serological test reagents such as transfusion-related reagents, allergy-related reagents, cancer marker related reagents, and other reagents.

Employees

133

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
10/26/10	2,268.00 ¥	0.00%	2,700
09/26/09	2,268.00 ¥	0.00%	1,200

Delayed Quote Japan Exchange

More quotes

Market Closed - Japan Exchange Other stock markets 12:00:00 10/06/2026 pm IST			5-day change	1st Jan Change
2,268.00 ^JPY	0.00%		0.00%	+78.44%

22/04	Kainos Laboratories Inc - to retire treasury shares worth 3.6% of outstanding stock on Jun 12	RE
25/03	Denka Company Limited completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders.	CI

Market Cap	113.55Cr 98Cr 90Cr 85Cr 158.73Cr 11TCr 160.32Cr 1.06TCr 415.96Cr 5.26TCr 426.13Cr 417.11Cr 18TCr	P/E Ratio 2009	3.96x	P/E Ratio 2010	13.8x
Enterprise Value	204.43Cr 176.2Cr 162.17Cr 152.13Cr 285.77Cr 19TCr 288.62Cr 1.92TCr 748.86Cr 9.46TCr 767.18Cr 750.93Cr 33TCr	EV / Sales 2009	0.43x	EV / Sales 2010	0.55x
Free-Float	3.88%	Yield 2009	2.68%	Yield 2010	2.38%

22/04	Kainos Laboratories Inc - to retire treasury shares worth 3.6% of outstanding stock on Jun 12	RE
25/03	Denka Company Limited completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders.	CI
09/02	Denka Company Limited proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders for ¥7.9 billion.	CI
09/02	Denka Unit Launches Tender Offer for Kainos Laboratories	MT
06/02	Denka Co Ltd - Will launch tender offer for Kainos shares	RE
18/24/18	Italian stationery maker FILA cuts stake in listed Indian unit DOMS	RE
14/22/14	KAINOS Laboratories, Inc. announced that it has received ¥250.47 million in funding from Sysmex Corporation	CI
25/22/25	KAINOS Laboratories, Inc. announced that it expects to receive ¥250.47 million in funding from Sysmex Corporation	CI
26/21/26	Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2021.	CI
26/21/26	KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2021, has closed with 150,000 shares, representing 3.66% for ¥158.1 million.	CI
25/21/25	KAINOS Laboratories, Inc. announces an Equity Buyback for 150,000 shares, for ¥158.1 million.	CI
25/21/25	KAINOS Laboratories, Inc. authorizes a Buyback Plan.	CI
26/20/26	Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2020.	CI

Current month	+0.18%
1 month	-0.22%
3 months	-0.53%
6 months	+80.29%
Current year	+78.44%

KAINOS Laboratories, Inc. Share Price

Stocks

4556

JP3205650009

Medical Equipment, Supplies & Distribution

Valuation: KAINOS Laboratories, Inc.

Chart: KAINOS Laboratories, Inc.

Latest news : KAINOS Laboratories, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: KAINOS Laboratories, Inc.

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

1 week	2,268	2,268
1 month	2,263	2,277
Current year	1,257	2,284
1 year	1,204	2,284
3 years	1,005	2,284
5 years	929	2,284
10 years	488	2,284

Manager	Title	Age	Since
Yukihiro Nagatsu PSD	President	66	01/04/2022
Tsukasa Hayashi ADM	Chief Administrative Officer	64	01/06/2016
Nobuaki Nakano PRN	Corporate Officer/Principal	62	01/07/2024

Director	Title	Age	Since
Yukihiro Nagatsu BRD	Director/Board Member	66	01/06/2014
Tsukasa Hayashi BRD	Director/Board Member	64	01/06/2014
Kenji Kikuchi BRD	Director/Board Member	74	01/06/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KAINOS LABORATORIES, INC.	0.00%	0.00%	+83.79%	+122.35%	6.3Cr
GUARDANT HEALTH, INC.	+0.96%	+0.00%	+163.95%	+250.84%	1.72TCr
BIOMÉRIEUX	+0.74%	-4.77%	-43.79%	-26.47%	923.08Cr
LANTHEUS HOLDINGS, INC.	+0.52%	+6.00%	+36.18%	+20.06%	681.47Cr
CARIS LIFE SCIENCES, INC.	0.00%	+6.90%	-	-	513.91Cr
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-1.12%	-3.49%	-28.64%	-32.34%	506.86Cr
ANDON HEALTH CO., LTD.	+5.84%	+4.31%	+96.02%	+93.66%	414.18Cr
DIASORIN S.P.A.	-0.65%	-5.46%	-28.86%	-33.64%	413.85Cr
10X GENOMICS, INC.	+1.57%	+7.09%	+197.55%	-43.62%	409.05Cr
AUTOBIO DIAGNOSTICS CO., LTD.	+2.66%	+6.26%	-14.34%	-40.87%	270.93Cr
Average	+1.08%	+3.97%	+51.32%	+34.44%	586.1Cr
Weighted average by Cap.	+0.97%	+3.35%	+66.80%	+75.06%

	2009	2010
Net sales	359.49Cr 309.84Cr 285.16Cr 267.51Cr 502.51Cr 34TCr 507.53Cr 3.37TCr 1.32TCr 17TCr 1.35TCr 1.32TCr 58TCr	421.51Cr 363.3Cr 334.35Cr 313.66Cr 589.2Cr 40TCr 595.08Cr 3.95TCr 1.54TCr 20TCr 1.58TCr 1.55TCr 68TCr
Net income	17Cr 14Cr 13Cr 12Cr 23Cr 1.59TCr 24Cr 157.28Cr 61Cr 776.22Cr 63Cr 62Cr 2.69TCr	10Cr 8.74Cr 8.05Cr 7.55Cr 14Cr 958.71Cr 14Cr 95Cr 37Cr 469.48Cr 38Cr 37Cr 1.62TCr
Net Debt	89Cr 77Cr 71Cr 66Cr 124.81Cr 8.44TCr 126.06Cr 837.31Cr 327.07Cr 4.13TCr 335.07Cr 327.97Cr 14TCr	91Cr 78Cr 72Cr 68Cr 127.04Cr 8.59TCr 128.3Cr 852.24Cr 332.9Cr 4.21TCr 341.04Cr 333.82Cr 15TCr